TIDMAGL
Angle PLC
09 October 2017
For immediate release 9 October 2017
ANGLE plc ("the Company")
ANGLE'S PARSORTIX(TM) SYSTEM SHOWCASED IN MULTIPLE PRESENTATIONS
AT LEADING EUROPEAN CIRCULATING TUMOUR CELL CONFERENCE
Traction of Company's CTC harvesting system accelerating as
customers and key opinion leaders feature Parsortix(TM) in 8
posters and five plenary presentations
Well positioned to become default cancer liquid biopsy
system
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, today announces that its Parsortix(TM) system was widely
showcased by the Company's customers and Key Opinion Leaders in the
field of circulating tumour cells (CTCs) in presentations at
Europe's leading CTC conference, the Third International Advances
in Circulating Tumour Cells (ACTC) Symposium, which recently took
place in Rhodes, Greece, 4 to 7 October 2017.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The significant number of presentations featuring Parsortix(TM)
at this leading conference for advances in the field of circulating
tumour cells suggests that ANGLE's strategy of promoting research
use sales to drive widespread adoption of its CTC harvesting system
is working well. Parsortix(TM) is compatible with numerous
downstream analysis systems and our aim is for it to become the
default system for cancer liquid biopsy, a growing market that is
expected to reach $14 billion in the United States alone by
2025."
ANGLE's Parsortix(TM) system was showcased in the following 8
different poster presentations and five plenary presentations (It
was also referenced by speakers in multiple other
presentations):
Plenary presentations
1) University of Athens ACTC Lab: CTC molecular characterisation
2) University Medical Center Hamburg-Eppendorf: Comprehensive
comparison of label independent CTC enrichment platform
3) Cancer Research UK Manchester Institute: Molecular status and
heterogeneity in small cell lung cancer
4) University of Maryland: Parsortix(TM) system central to
potential new analytical protocol for identifying drugs that may
arrest metastasis (see separate announcement released today)
5) Bayer Pharma: Cancer ID project cancer treatment and monitoring
Poster Presentations
1) Heinrich-Heine University Duesseldorf: EpCAM low/negative CTCs in metastatic breast cancer
2) Barts Cancer Institute: CTCs and megakaryocytes in prostate cancer prognosis
3) Cancer Research UK Manchester Institute: molecular profiling
of CTCs in non-small cell lung cancer
4) Heinrich-Heine University Düsseldorf: Circulating tumour
cells, harvested from blood, grown in laboratory for the first time
(see separate announcement released today)
5) University of Tuebingen: Separation of cancer cells
6) Synexa Life Sciences: Capture and characterisation of colorectal cancer CTCs
7) University Hospital Ghent, Belgium: Optimising workflow for transcriptome analysis of CTCs
8) University of Athens: PD-L1 and CK-19 gene expression in CTCs
using Parsortix compared to EpCAM-based isolation in head and neck
cancer
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes +44 (0) 203 705 9318
Nigel Birks +44 (0) 203 705 9316
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. Parsortix has a CE Mark for Europe and
FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADGBDGCGGBGRI
(END) Dow Jones Newswires
October 09, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024